8 results about "Glucal" patented technology

This invention discloses a method for preparing a highly water-resistant, glue-free, synergistically cross-linked bamboo-based board, comprising the following steps: preparing polyphenol-modified bamboo powder; adding glucuronic acid solution dropwise to the polyphenol-modified bamboo powder, reacting at 50℃~65℃, then adding citric acid solution, and reacting again to obtain cross-linked modified bamboo powder; adjusting the moisture content of the cross-linked modified bamboo powder to 8wt%~12wt%, and pre-pressing it into a blank; covering the upper and lower surfaces of the blank with a release film and a steel plate respectively, then placing it in a flatbed hot press, and performing segmented pressing molding at 155℃~165℃ to obtain the highly water-resistant, glue-free, synergistically cross-linked bamboo-based board. The resulting board requires no traditional adhesives, possesses high mechanical strength, excellent water resistance, and dimensional stability, and the process is mild with green raw materials, making it suitable for the field of green building materials and providing a new approach for the efficient utilization of bamboo resources.

The present application relates to the technical field of drug residue detection, and in particular to a general pre-treatment method based on immunoaffinity rapid detection. A general pre-treatment method based on immunoaffinity rapid detection, comprising the following steps: using reagent 1, reagent 2, reagent 3, reagent 4, reagent 5 to process the sample to be tested in sequence, wherein the reagent 1 is ammonium citrate buffer; the reagent 2 is β-glucuronidase; the reagent 3 is arylsulfatase; the reagent 4 is a mixture of acetonitrile, methanol, ethanol and an organic acid; the organic acid is citric acid or formic acid; the reagent 5 is N-propylethylenediamine. The pre-treatment method of the present application is applicable to the pre-treatment of the residue detection of multiple major drugs involved in veterinary drug residues in current animal food, and solves the problem that food safety detection usually requires the determination of multiple drugs on the same sample, and multiple pre-treatment operations are required, and the time, equipment and reagent consumption are large.

This invention discloses an engineered bacterial strain for producing xylitol using glucose as the sole carbon source, its construction method, and its applications, belonging to the field of genetic engineering. Using *Escherichia coli* as the starting strain, this invention optimizes the metabolic pathway by knocking out the 2-keto-3-deoxy-6-phosphate glucuronide gene (eda), knocking out the 6-phosphoglucuronide dehydratase gene (edd), and weakening the glucose phosphoisomerase gene (pgi), thus concentrating the carbon flow in the pentose phosphate pathway. Furthermore, it optimizes the metabolic pathway by knocking out or overexpressing endogenous genes such as the ribulokinase gene (araB). Subsequently, the synthesis of xylitol from glucose was experimentally tested by expressing a recombinant expression plasmid containing 2-arabinol dehydrogenase, 4-arabinol dehydrogenase, and xylitol dehydrogenase. This invention, through optimized metabolic pathways, efficiently converts glucose to xylitol without the need for glycerol addition, and significantly increases the yields of both the precursor arabinol and the product xylitol, demonstrating promising production prospects.

The invention provides a construction method of an animal model of senile prediabetic disease, which comprises the following steps: performing intragastric administration induction on an experimental animal by using 3-deoxyglucuronidone to construct and form the animal model of senile prediabetic disease with impaired fasting blood glucose and / or hypoglucose tolerance as a main marker. Researches find that 3-deoxyglucal not only induces glucose and lipid metabolism disorder and peripheral adipose tissue insulin resistance and islet secretion function damage, but also causes'fat-islet axis' dual hormone feedback loop imbalance, and is mainly related to interaction damage of adiponectin / adiponectin receptor pathway and glucose / sweet receptor pathway. The composition accords with physiological and pathological characteristics of senile prediabetic diseases. The model provided by the invention has the advantages of prevention, treatment and reversibility, is simple to operate, economical and applicable, and high in modeling success rate, solves the core problem of complexity of the existing animal model for the senile prediabetic disease, and provides an experimental basis for research and development of related drugs.

A method of preparing glucodiamine, comprising contacting glucose with an enzyme oxidation catalyst under conditions suitable for the formation of glucodialdose; contacting glucodialdose with a nitrogen-containing compound under conditions suitable for the formation of glucodioxime; and reducing glucodioxime under conditions suitable for the formation of glucodiamine. A method of preparing glucodiamine, comprising contacting glucodioxime with a dehydration catalyst under conditions suitable for the formation of glucodinitrile; and reducing glucodinitrile under conditions suitable for the formation of glucodiamine. A chemoenzymatic method of producing a bio-based amide platform chemical, comprising: contacting glucose with a biocatalyst under conditions suitable for the formation of glucodialdose; contacting glucodialdose with a base under conditions suitable for the formation of glucodioxime; and contacting glucodioxime with a hydrogenation catalyst in the presence of hydrogen under conditions suitable for formation of glucodiamine.

A method for stereoselectively synthesizing β - oxygen glycosides based on 3 - O -quinolinate enose donors comprises the following steps: using 3 - O -quinolinate glucal as the enose donor, adding a catalyst, a ligand, triethylamine, a sugar acceptor and an organic solvent, stirring at 50 - 70 °C, monitoring the reaction progress by TLC. When the 3 - O -quinolinate glucal raw material completely disappears, terminate the reaction to obtain β - 2,3 - unsaturated oxygen glycoside. In the technical solution of the present invention, the quinolinate at the C - 3 position of the enose donor is a good leaving group and can easily form a π - allylpalladium intermediate under palladium catalysis. Subsequently, the acceptor attacks the anomeric carbon from the β - face to obtain a β - 2,3 - unsaturated glycoside oxygen product without the generation of rearrangement by - products. Triethylamine is added to the reaction system to make the reaction solution weakly alkaline, and the obtained β - 2,3 - unsaturated glycoside oxygen product is not easily hydrolyzed.

The application provides a detection method and identification method of a characteristic spectrum of vinegar stellariae formula granules, wherein the identification method of stellariae includes: obtaining a characteristic spectrum of a to-be-detected object, and comparing the characteristic spectrum with a standard characteristic spectrum of vinegar stellariae formula granules; wherein the characteristic spectrum of the to-be-detected object contains a characteristic peak corresponding to isoquercitrin, and does not contain a characteristic peak corresponding to hydroxyl stellariae; the to-be-detected object is kadsurae; the to-be-detected object contains a characteristic peak corresponding to hydroxyl stellariae, and does not contain a characteristic peak corresponding to isoquercitrin; and when a relative peak area of a peak where chlorogenic acid is located is not greater than 0.2 compared with a peak where apigenin-7-O-beta-D-glucuronide is located, the to-be-detected object is stellariae; when the characteristic spectrum of the to-be-detected object contains characteristic peaks corresponding to isoquercitrin and hydroxyl stellariae, the to-be-detected object is stellariae striata. The application can quickly and effectively distinguish kadsurae, stellariae and stellariae striata.

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.